Targeting PD-L1 in non-small cell lung cancer using CAR T cells
Abstract Antibodies against programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the landscape of therapies for non-small cell lung carcinoma (NSCLC); however, the majority of patients do not respond to these agents. In addition, hyperprogressive disease (HPD) deve...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Béarla |
| Foilsithe / Cruthaithe: |
2020
|
| Rochtain ar líne: | https://doi.org/10.1038/s41389-020-00257-z https://www.nature.com/articles/s41389-020-00257-z.pdf |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Bí ar an gcéad duine le trácht a dhéanamh!